Johnson & Johnson’s Covid-19 vaccine candidate begins phase 3 trials in the United States on Wednesday. Trials for the single-dose vaccine, which uses a human adenovirus, will include up to 60,000 adult participants at nearly 215 sites in the US and internationally. The vaccine candidate was developed by Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson. Phase 3 trials will begin immediately, with the first participants receiving doses Wednesday, Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels said on a call with reporters Tuesday. https://www.cnn.com/world/live-news/coronavirus-pandemic-09-23-20-intl/h_f1f6bbdcf10dda4405a4cb813bd88fba
The vaccine candidate was developed by Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson. Phase 3 trials will begin immediately, with the first participants receiving doses Wednesday, Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels said on a call with reporters Tuesday.
https://www.cnn.com/world/live-news/coronavirus-pandemic-09-23-20-intl/h_f1f6bbdcf10dda4405a4cb813bd88fba
国内的是人类腺病毒的,Ad5,大多数人多Ad5免疫。 这个是Ad26,人体免疫率很低,没有ad5的预存免疫现象。 国内那个ad5就是骗经费糊弄人的。陈薇之前弄的sars 埃博拉疫苗都用的ad5,一个都没上市。,
没有,英国有一个开始搞灭活疫苗的公司